AnaptysBio, Inc. (ANAB) Stock

AnaptysBio, Inc. (ANAB) is a Healthcare stock trading at $57.49 (as of 2026-06-18), with a market capitalization of $1.49B and a trailing P/E of -55.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AnaptysBio, Inc. is a clinical-stage biotechnology company developing therapeutic antibody product candidates for inflammation and immuno-oncology. Its programs include Imsidolimab targeting the IL-36 receptor, rosnilimab as an anti–PD-1 agonist strategy, and ANB032 targeting BTLA, which are advanced through preclinical and clinical development, including under collaborations and licenses.

Valuation — source: SEC EDGAR (first-party)

Price	$57.49
Market Cap	$1.49B
P/E Ratio	-55.0
EV / EBITDA	33.5
Price / Book	128.01
Price / Sales	7.02
DCF Value (model)	$19.66
DCF Upside vs Price	-65.8%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$234.60M
Net Margin	-5.6%
Return on Equity	-210.1%
Current Ratio	7.58
Revenue Growth (YoY)	157.0%
EPS Growth (YoY)	-91.0%
FCF Growth (YoY)	-114.5%

Financial Health — source: SEC EDGAR

Altman Z-Score

2.20 (grey)

Valuation vs Sector & Industry

Stock P/E	-55.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-362.3%
vs Industry	-418.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	EcoR1 Capital, LLC ($437.03M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Daniel R. Faga
Employees	136
Country	US
IPO Date	2017-01-26

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Rapport Therapeutics, Inc. Common Stock (RAPP)
• Ardelyx, Inc. (ARDX)
• MBX Biosciences, Inc. Common Stock (MBX)
• Tyra Biosciences, Inc. (TYRA)
• Immatics N.V. (IMTX)
• Amylyx Pharmaceuticals, Inc. (AMLX)
• Schrödinger, Inc. (SDGR)
• Palvella Therapeutics, Inc. (PVLA)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.